At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

PHILADELPHIA, PA—Dapagliflozin added to optimal medical therapy results in meaningful improvements in symptoms and health-related quality of life in heart failure patients with reduced ejection ...

Dapagliflozin Benefits Low-EF Heart Failure Regardless of Diuretic Dose: DAPA-HF Steve Stiles June 10, 2020 0 ...

June 29, 2011 (San Diego, California) — Dapagliflozin in combination with metformin was found to increase blood glucose lowering compared with either agent alone in patients with newly diagnosed ...